| hydrochlorothiazide / Generic mfg. |
NCT00282178 / 2004-005013-11: Double-Blind Randomized Cross-Over Trial Comparing Metabolic Effects of Candesartan, Hydrochlorothiazide and Placebo |
|
|
| Completed | 2 | 26 | Europe | Hydrochlorothiazide, Placebo, Candesartan | Umeå University, Sahlgrenska University Hospital, Sweden, AstraZeneca | Hypertension, Obesity | 03/06 | 04/06 | | |
ChiCTR2000041306: II period clinical research of compound candesartan ester (candesartan ester 16 mg/hydrochlorothiazide 12.5 mg) in the treatment of Chinese patients with primary hypertension |
|
|
| Completed | 2 | 276 | | Candesartan 16mg was taken ;Compound Candesartan ester (Can16/HCTZ12.5) ;Candesartan 8mg | Institute of Fuwai Cardiovascular Disease Hospital, Chinese Academy of Medical Sciences; Jiangsu Deyuan Pharmaceutical Co., Ltd., Fully self-financing | Hypertension | | | | |
| Completed | 2 | 153 | Europe | PPAR alpha, Hydrochlorothiazide, Placebo | Eli Lilly and Company | Mild Hypertension | | 11/06 | | |
NCT00089713: Systolic Pressure Efficacy and Safety Trial of Alagebrium (SPECTRA) |
|
|
| Terminated | 2 | 392 | US | alagebrium chloride (ALT-711) | Synvista Therapeutics, Inc | Hypertension | | | | |
| Completed | 2 | 154 | US, Canada, Europe | Dapagliflozin, BMS-512148, Placebo, Hydrochlorothiazide | AstraZeneca, Astra Zeneca, Bristol-Myers Squibb | Type 2 Diabetes Mellitus | 11/10 | 11/10 | | |
|
NCT01096667: Study of Safety and Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes And Hypertension (MK-8835-042) |
|
|
| Completed | 2 | 194 | NA | Placebo to Ertuglilflozin 1 or 5 mg, Ertugliflozin 1 mg, Ertugliflozin 5 mg, Ertugliflozin 25 mg, HCTZ 12.5mg, Placebo to HCTZ, Placebo to ertuglilflozin 25 mg | Merck Sharp & Dohme LLC, Pfizer | Diabetes Mellitus, Type 2, Hypertension | 02/11 | 02/11 | | |
AVEC, NCT00605072: The Antihypertensives and Vascular, Endothelial and Cognitive Function Trial |
|
|
| Completed | 2 | 53 | US | candesartan, Atacand, lisinopril, Prinivil, hydrochlorothiazide, HCTZ, multiple brand names, nifedipine, long acting, Procardia XL, metoprolol, long-acting, Lopressor, Toprol XL | University of Southern California, National Institute on Aging (NIA), Hebrew SeniorLife | Cognitive Impairment, Hypertension, Aging | 12/11 | 12/12 | | |
NCT01256411: A Long-term (12 Months) Safety, Tolerability and Efficacy Study of LCZ696 in Patients With Essential Hypertension |
|
|
| Completed | 2 | 341 | Japan, RoW | LCZ696, Amlodipine, Hydrochlorothiazide (HCTZ) | Novartis Pharmaceuticals | Essential Hypertension | 04/12 | 04/12 | | |
NCT01480791: Aliskiren vs Hydrochlorothiazide in Hypertensive Type II Diabetic Patients on Resistance Arteries |
|
|
| Withdrawn | 2 | 0 | Canada | Aliskiren vs. hydrochlorothiazide, Aliskiren is Tekturna or Rasilez, Hydrochlorothiazide, Hydrochlorothiazide is a generic drug. | Sir Mortimer B. Davis - Jewish General Hospital, Novartis Pharmaceuticals | Hypertension, Diabetes | 12/13 | 12/13 | | |
| Completed | 2 | 454 | Japan, US, Europe, RoW | LCZ696, sacubitril/valsartan, Olmesartan, LCZ696 matching placebo, Olmesartan matching placebo, amlodipine, hydrochlorothiazide | Novartis Pharmaceuticals | Hypertension | 04/15 | 04/15 | | |
NCT02222480: A Clinical Trial to Evaluate Efficacy, Tolerability, and Pharmacokinetic-Pharmacodynamic Relationship of Fimasartan/Hydrochlorothiazide |
|
|
| Completed | 2 | 103 | RoW | Fimasartan, Hydrochlorothiazide, Placebo | Boryung Pharmaceutical Co., Ltd, Seoul National University Hospital | Hypertension | 05/15 | 06/15 | | |
2017-003864-10: Medication for excessive urine production in patients treated with tolvaptan Medicijnen tegen verhoogde urineproductie bij tolvaptan |
|
|
| Ongoing | 2 | 12 | Europe | Hydrochlorothiazide, Metformin, HCT, Tablet | University Medical Center Groningen, University Medical Center Groningen | Autosomal dominant polycystic kidney disease Autosomaal dominante polycysteuze nierziekte, Polycystic kidney disease Familiaire cystenieren, Diseases [C] - Symptoms and general pathology [C23] | | | | |
HYDRA, NCT03658850: Safety and Efficacy of Hydrochlorothiazide in the Treatment of Hypernatremia in Critically Ill Patients |
|
|
| Unknown status | 2 | 184 | RoW | Hydrochlorothiazide 50Mg, Placebos | University of Sao Paulo | Hypernatremia, Critical Illness | 12/19 | 03/20 | | |
2016-000500-29: A randomized Crossover TrIal to Compare recombinant human rhPTH(1-34) to the ASsociation alfacalcidol/hydrochlorothiazide in the treatment of Autosomal Dominant Hypocalcemia Essai croisé randomisé comparant la PTH (1-34) recombinante humaine à l'association alfacalcidol/hydrochlorothiazide dans le traitement de l'hypocalcémie autosomique dominante |
|
|
| Not yet recruiting | 2 | 25 | Europe | FORSTEO-R, ESIDREX-R 25 mg, UN-ALPHA-R 0.25µg, Solution for injection, Tablet, Capsule, FORSTEO-R, ESIDREX-R 25 mg, UN-ALPHA-R 0.25µg | ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | Autosomal dominant hypocalcemia (ADH) Hypocalcémie autosomique dominante (HAD), Autosomal dominant hypocalcemia (ADH) Hypocalcémie autosomique dominante (HAD), Diseases [C] - Hormonal diseases [C19] | | | | |
ACTICAS, NCT02824718: Recombinant Human rhPTH(1-34) VS Association Alfacalcidol/Hydrochlorothiazide in Severe Primary Hypoparathyroidism |
|
|
| Completed | 2 | 16 | Europe | Teriparatide, FORSTEO, Thiazide, ESIDREX, Potassium sparing diuretic, MODAMIDE, Alfacalcidol, UN-ALFA | Assistance Publique - Hôpitaux de Paris, Ministry of Health, France | Autosomal Dominant Hypocalcemia OR Primary Hypoparathyroidism Related to Other Cause But Complicated by Hypercalciuria Under Treatment | 05/20 | 05/20 | | |
| Terminated | 2 | 33 | US | Clonidine, Catapress, Hydrochlorothiazide, Placebo | Gary L. Pierce, American Heart Association | Obesity, Prehypertension, Hypertension | 06/20 | 06/20 | | |
| Recruiting | 2 | 99 | Europe | Indapamide 2.5 MG, Hydrochlorothiazide 50Mg, Chlorthalidone 25mg | Insel Gruppe AG, University Hospital Bern, University of Bern | Kidney Stone | 06/27 | 06/27 | | |
NCT03179163: Peripheral Vascular Effects of Sulfhydryl-containing Antihypertensive Pharmacotherapy on Microvessels in Humans |
|
|
| Terminated | 1/2 | 10 | US | Captopril Pill, National Drug Code (NDC) # 00781-8061-01, Enalapril Pill, NDC# 51672-4039-03, Hydrochlorothiazide, NDC# 00603-3857-32 | Penn State University, National Heart, Lung, and Blood Institute (NHLBI) | Hypertension,Essential | 08/22 | 12/22 | | |
